AI Article Synopsis
- The disease is complex, involving issues like skin barrier dysfunction, immune system imbalances, and changes in skin microbes, which all contribute to its symptoms.
- Treatments currently available include monoclonal antibodies like Dupilumab and tralokinumab for moderate-to-severe cases, with additional medications like lebrikizumab and nemolizumab in the pipeline.
Article Abstract
Atopic dermatitis (AD) is a common chronic pruritic inflammatory skin disease that affects all ages and is recognized as a global health problem. Pathophysiology is complex with skin barrier abnormalities, immune dysregulation, and microbial dysbiosis all implicated. Markers of immune and inflammatory activation in the circulation provide a rationale for systemic therapy. Type 2 immune polarization is central, though other cytokine pathways including Th22 and Th17/IL-23 have been described, suggesting additional therapeutic targets in a subset of patients. Dupilumab and tralokinumab are monoclonal antibodies currently approved for moderate-to-severe AD with lebrikizumab and nemolizumab in late stages of development.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.iac.2024.08.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!